ViewRay, Inc. (VRAY) News

ViewRay, Inc. (VRAY): $4.78

-0.03 (-0.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter VRAY News Items

VRAY News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRAY News Highlights

  • VRAY's 30 day story count now stands at 9.
  • Over the past 17 days, the trend for VRAY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about VRAY are TOP, PATH and AMP.

Latest VRAY News From Around the Web

Below are the latest news stories about VIEWRAY INC that investors may wish to consider to help them evaluate VRAY as an investment opportunity.

Morgan Stanley Remains a Hold on Viewray (VRAY)

E ratio of -7.85.

Catie Powers on TipRanks | November 18, 2022

Viewray (VRAY) Receives a Buy from BTIG

In a report released today, Marie Thibault from BTIG reiterated a Buy rating on Viewray (VRAY - Research Report), with a price target of $7.00. The company's shares closed yesterday at $4.45.According to TipRanks, Thibault is a 4-star analyst with an average return of 4.8% and a 35.74% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Viewray, Masimo, and Atricure.Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $6.38, implying a 43.37% upside from current levels. In a report released on November 2, Piper Sandler also maintained a Buy rating on the stock with a $6.50 price target.

Ryan Adist on TipRanks | November 15, 2022

ViewRay Expands Access to Non-Dilutive Capital With New Debt Facility

ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced that it has entered into a new five-year loan facility agreement with MidCap Financial and Silicon Valley Bank (the "Agreement"). The Agreement consists of a term loan of up to $100 million and a revolving line of credit of up to $25 million.

Yahoo | November 14, 2022

ViewRay® to Participate in the 34th Annual Piper Sandler Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the 34th Annual Piper Sandler Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 9:30 a.m. Eastern Time on Wednesday, November 30, 2022.

Yahoo | November 14, 2022

ViewRay® to Present at the Stifel 2022 Healthcare Conference

ViewRay, Inc. (NASDAQ: VRAY) announced today that the Company will present at the Stifel 2022 Healthcare Conference. Scott Drake, President and Chief Executive Officer, and Zach Stassen, Chief Financial Officer, will participate in a fireside chat at 2:25 p.m. Eastern Time on Tuesday, November 15, 2022.

Yahoo | November 10, 2022

ViewRay, Inc. (VRAY) Q3 2022 Earnings Call Transcript

ViewRay, Inc. (VRAY)

Q3 2022 Results Conference Call

November 01, 2022 05:00 PM ET

Company Participants

Matt Harrison - Director, IR

Scott Drake - President & CEO

Zach Stassen - CFO

Dr. Paul Strong - VP of Clinical Affairs

Conference Call Participants

Jason Bednar - Piper Sandler

Rick Wise - Stifel

Marie Thibault - BTIG

Mike Ott - Opp Co

Young Li - Jefferies

Presentation

Operator

Good day and thank you for standing by. Welcome everyone to the ViewRay Third Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' remarks, there will be a question-and-answer session. [Oper...

SA Transcripts on Seeking Alpha | November 2, 2022

Analysts’ Top Healthcare Picks: Waters (WAT), Viewray (VRAY)

Analysts fell to the sidelines weighing in on Waters (WAT – Research Report) and Viewray (VRAY – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Waters (WAT) In a report released today, Timothy Daley from Wells Fargo maintained a Hold rating on Waters, with a price target of $320.00. The company's shares closed last Wednesday at $302.74. According to TipRanks.

Howard Kim on TipRanks | November 2, 2022

ViewRay (VRAY) Reports Q3 Loss, Tops Revenue Estimates

ViewRay (VRAY) delivered earnings and revenue surprises of 0% and 4.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 1, 2022

ViewRay Announces Third Quarter 2022 Results

ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022.

Yahoo | November 1, 2022

MIRAGE Phase III Randomized Controlled Trial Demonstrates Superiority of MRIdian® MRI-Guidance in Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer

ViewRay, Inc. (NASDAQ: VRAY) announced today that the final primary endpoint results from the phase III randomized single-center MIRAGE trial were presented at the 64th Annual Meeting of the American Society for Radiation Oncology (ASTRO) being held October 23-26, 2022, at the Henry B. Gonzalez Convention Center in San Antonio, Texas. The trial was independently conducted by investigators at UCLA and compared MRIdian MRI-guided SBRT vs. CT-guided SBRT for localized prostate cancer.

Yahoo | October 27, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6783 seconds.